| Name | Title | Contact Details |
|---|
We are dedicated to developing lifesaving and life-altering treatments that can empower patients affected by rare immunologic conditions to live longer and healthier lives.
Mitsubishi Tanabe Pharma Development America is a Warren, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. As a key common element in a variety of serious, debilitating diseases, mitochondria – the cell’s energy source – offer a promising, and yet untapped target to modify diseases with significant unmet treatment needs. Stealth is expanding its clinical development program to additional therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, Stealth is leading mitochondrial medicine.
BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.
Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness`s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases.